載入...
Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) might be new therapeutic strategies for advanced non-small cell lung cancer (NSCLC). Here a total of 12,520 patients from 23 randomized controlled trials (RCTs) were enrolled to evaluate the efficacy and safety of VE...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4627246/ https://ncbi.nlm.nih.gov/pubmed/26156021 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|